Giuseppe
Emeritus
[Source: Clinical Infectious Diseases, full page: (LINK). Abstract, edited.]
Vitamin D<SUB>3</SUB> Supplementation and Upper Respiratory Tract Infections in a Randomized, Controlled Trial
Judy R. Rees 1, Kristy Hendricks 2, Elizabeth L. Barry 1, Janet L. Peacock 1,3,4, Leila A. Mott 1, Robert S. Sandler 5, Robert S. Bresalier 6, Michael Goodman 7, Roberd M. Bostick 7, and John A. Baron 1,5
Author Affiliations: <SUP>1</SUP>Department of Community and Family Medicine, Section of Biostatistics and Epidemiology; <SUP>2</SUP>Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; <SUP>3</SUP>Division of Health and Social Care Research, King's College London; <SUP>4</SUP>NIHR Biomedical Research Centre at Guy's and St Thomas? NHS Foundation Trust and King's College London, United Kingdom; <SUP>5</SUP>Department of Medicine, University of North Carolina School of Medicine, Chapel Hill; <SUP>6</SUP>Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston; <SUP>7</SUP>Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia
Correspondence: Judy R. Rees, BM, BCh, PhD, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, HB 7927, Lebanon, NH 03756 (judy.rees@dartmouth.edu).
Abstract
Background.
Randomized controlled trials testing the association between vitamin D status and upper respiratory tract infection (URTI) have given mixed results. During a multicenter, randomized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D<SUB>3</SUB> supplementation reduced winter episodes and duration of URTI and its composite syndromes, influenza-like illness (ILI; fever and ≥2 of sore throat, cough, muscle ache, or headache) and colds (no fever, and ≥2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen or tender neck glands).
Methods.
The 2259 trial participants were aged 45?75, in good health, had a history of colorectal adenoma, and had a serum 25-hydroxyvitamin D level ≥12 ng/mL. They were randomized to vitamin D<SUB>3</SUB> (1000 IU/day), calcium (1200 mg/day), both, or placebo. Of these, 759 participants completed daily symptom diaries. Secondary data included semiannual surveys of all participants.
Results.
Among those who completed symptom diaries, supplementation did not significantly reduce winter episodes of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI], .79?1.09) including colds (RR, 0.93; 95% CI, .78?1.10) or ILI (RR, 0.95; 95% CI, .62?1.46), nor did it reduce winter days of illness (RR, 1.13; 95% CI, .90?1.43). There was no significant benefit according to adherence, influenza vaccination, body mass index, or baseline vitamin D status. Semiannual surveys of all participants (N = 2228) identified no benefit of supplementation on ILI (odds ratio [OR], 1.14; 95% CI, .84?1.54) or colds (OR, 1.03; 95% CI, .87?1.23).
Conclusions.
Supplementation with 1000 IU/day vitamin D<SUB>3</SUB> did not significantly reduce the incidence or duration of URTI in adults with a baseline serum 25-hydroxyvitamin D level ≥12 ng/mL.
Key words
upper respiratory tract infection - vitamin D - randomized controlled trial
Received May 2, 2013. Accepted August 9, 2013.
? The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com.
-
-------
Vitamin D<SUB>3</SUB> Supplementation and Upper Respiratory Tract Infections in a Randomized, Controlled Trial
Judy R. Rees 1, Kristy Hendricks 2, Elizabeth L. Barry 1, Janet L. Peacock 1,3,4, Leila A. Mott 1, Robert S. Sandler 5, Robert S. Bresalier 6, Michael Goodman 7, Roberd M. Bostick 7, and John A. Baron 1,5
Author Affiliations: <SUP>1</SUP>Department of Community and Family Medicine, Section of Biostatistics and Epidemiology; <SUP>2</SUP>Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; <SUP>3</SUP>Division of Health and Social Care Research, King's College London; <SUP>4</SUP>NIHR Biomedical Research Centre at Guy's and St Thomas? NHS Foundation Trust and King's College London, United Kingdom; <SUP>5</SUP>Department of Medicine, University of North Carolina School of Medicine, Chapel Hill; <SUP>6</SUP>Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston; <SUP>7</SUP>Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia
Correspondence: Judy R. Rees, BM, BCh, PhD, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, HB 7927, Lebanon, NH 03756 (judy.rees@dartmouth.edu).
Abstract
Background.
Randomized controlled trials testing the association between vitamin D status and upper respiratory tract infection (URTI) have given mixed results. During a multicenter, randomized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D<SUB>3</SUB> supplementation reduced winter episodes and duration of URTI and its composite syndromes, influenza-like illness (ILI; fever and ≥2 of sore throat, cough, muscle ache, or headache) and colds (no fever, and ≥2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen or tender neck glands).
Methods.
The 2259 trial participants were aged 45?75, in good health, had a history of colorectal adenoma, and had a serum 25-hydroxyvitamin D level ≥12 ng/mL. They were randomized to vitamin D<SUB>3</SUB> (1000 IU/day), calcium (1200 mg/day), both, or placebo. Of these, 759 participants completed daily symptom diaries. Secondary data included semiannual surveys of all participants.
Results.
Among those who completed symptom diaries, supplementation did not significantly reduce winter episodes of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI], .79?1.09) including colds (RR, 0.93; 95% CI, .78?1.10) or ILI (RR, 0.95; 95% CI, .62?1.46), nor did it reduce winter days of illness (RR, 1.13; 95% CI, .90?1.43). There was no significant benefit according to adherence, influenza vaccination, body mass index, or baseline vitamin D status. Semiannual surveys of all participants (N = 2228) identified no benefit of supplementation on ILI (odds ratio [OR], 1.14; 95% CI, .84?1.54) or colds (OR, 1.03; 95% CI, .87?1.23).
Conclusions.
Supplementation with 1000 IU/day vitamin D<SUB>3</SUB> did not significantly reduce the incidence or duration of URTI in adults with a baseline serum 25-hydroxyvitamin D level ≥12 ng/mL.
Key words
upper respiratory tract infection - vitamin D - randomized controlled trial
Received May 2, 2013. Accepted August 9, 2013.
? The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com.
-
-------